Assessment of circulating blood lymphocytes in adult patients on rituximab to treat immune thrombocytopenia: Circulating number of NK cells is associated with the response at 6 months
British Journal of Haematology · 2023
DOI: 10.1111/bjh.18818 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2023. Verfasst von Etienne Rivière und 7 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine and Infectious Diseases Unit, Haut-Leveque Hospital, University Hospital Centre of Bordeaux, Pessac, France. Hauptthemen laut MEDLINE: Purpura, Thrombocytopenic, Idiopathic, Thrombocytopenia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Immune thrombocytopenia (ITP) is defined by a low platelet count that can trigger potentially life‐threatening haemorrhages. Three‐quarters of adult patients exhibit persistent or chronic disease and require second‐line treatments. Among these, rituximab, an anti‐CD20 antibody, has yielded valuable results, with global responses in 60% of patients at 6 months and complete responses in 30% at 5 years. Factors predictive of response to ITP therapy would help physicians choose optimal treatments. We retrospectively analysed clinical courses, biological markers and blood lymphocyte subset numbers of 72 patients on rituximab to treat persistent/chronic ITP followed‐up in our department between 2007 and 2021, divided into three groups according to the platelet count at 6 months: complete, partial or no response. Among all studied parameters, a low number of CD3 − CD16 + CD56 + circulating NK cells was associated with the complete response to rituximab. We also found that, after rituximab therapy, complete responders exhibited increased NK and decreased activated CD8 + T cell percentages. These results emphasize that the role played by NK cells in ITP remains incompletely known but that factors predictive of response to rituximab can be easily derived using blood lymphocyte subset data.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Internal Medicine and Infectious Diseases Unit, Haut-Leveque Hospital, University Hospital Centre of Bordeaux, Pessac, France.
- INSERM U1034, Bordeaux University, Pessac Cedex, France.
- Department of Public Health, University of Bordeaux, INSERM U1219 Bordeaux Population Health Research Centre, Inria SISTM, UMR 1219, Bordeaux, France.
- Department of Medical Information, University Hospital Centre of Bordeaux, Bordeaux, France.
- UMR CNRS 5164, ImmunoconcEpT & FHU ACRONIM, Bordeaux University, Bordeaux, France.
- Laboratory of Hematology, Haut-Leveque Hospital, University Hospital Centre of Bordeaux, Pessac, France.
ORCID-Profile: Etienne Rivière, Jean-François Viallard
Zitieren
APA
Rivière, E., Thiébaut, R., Lazaro, E., Guy, A., James, C., Mansier, O., Blanco, P., & Viallard, J. F. (2023). Assessment of circulating blood lymphocytes in adult patients on rituximab to treat immune thrombocytopenia: Circulating number of NK cells is associated with the response at 6 months. British Journal of Haematology. https://doi.org/10.1111/bjh.18818
Vancouver
Rivière E, Thiébaut R, Lazaro E, Guy A, James C, Mansier O, et al. Assessment of circulating blood lymphocytes in adult patients on rituximab to treat immune thrombocytopenia: Circulating number of NK cells is associated with the response at 6 months. British Journal of Haematology. 2023. doi:10.1111/bjh.18818
BibTeX
@article{Rivire2023,
author = {Rivière, Etienne and Thiébaut, Rodolphe and Lazaro, Estibaliz and Guy, Alexandre and James, Chloé and Mansier, Olivier and Blanco, Patrick and Viallard, Jean-François},
title = {Assessment of circulating blood lymphocytes in adult patients on rituximab to treat immune thrombocytopenia: Circulating number of NK cells is associated with the response at 6 months},
journal = {British Journal of Haematology},
year = {2023},
doi = {10.1111/bjh.18818}
}
EUVIMED